Haemonetics Corporation (HAE)
NYSE: HAEHealth CareMedical/Dental InstrumentsUSD
Market open · Delayed 15 min · as of Oct 8, 10:03 AM ET
HAE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.27B
- P/E (TTM)
- 55.94
- Forward P/E
- 20.04
- EPS (TTM)
- $2.07
- Dividend yield
- None
- 52-week range
- 48.17 – 120.72
- Day range
- 111.66 – 120.72
- Volume / Avg
- 829.13K / 678.94K
- Beta
- —
- Shares outstanding
- 45.50M
- Next earnings
- Nov 5, 2026
52-week range
HAE stock today
Shares of Haemonetics (HAE) are trading higher on Oct 8 at $115.80, a gain of 13.85% or $14.09 per share, versus the S&P 500's 0.27% decline. At this level, HAE sits near the top of its 52-week range of $48.17 to $120.72: 4.1% below the high and 140.4% above the low. HAE is up 26.9% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 106.5%.
At 55.9x trailing earnings, Haemonetics trades above the peer-group median of 36.8x. Its forward P/E of 20.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Haemonetics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Haemonetics
Company profileHaemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Christopher A. Simon
- Headquarters
- Boston, MA
- Employees
- 3,009
- IPO year
- 1991
- Website
- haemonetics.com
Financial highlights
Full financialsIn fiscal 2026, Haemonetics generated $1.33 billion in revenue, down 2.0% from fiscal 2025, its first annual decline since 2021. Net income was $97.3 million (-42.0% year over year), for a net margin of 7.3% versus a median of 9.1% in the prior 5 years. Gross margin was 59.0% (up from 55.0%) and operating margin 11.7%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $1.33B | $1.36B | $1.31B | $1.17B | $993.20M |
| Growth | -1.97% | +3.95% | +12.01% | +17.67% | +14.10% |
| Net income | $97.31M | $167.68M | $117.56M | $115.40M | $43.38M |
| EPS (diluted) | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 |
Analyst forecast
ForecastConsensus (11 analysts)
buy
Avg. price target
$111.50-3.71%
- Strong buy 4
- Buy 5
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $1.30
- Last reported (Q1 2027)
- Aug 6, 2026
- EPS actual vs est.
- $0.72 vs —
HAE news
All HAE newsHaemonetics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MMSIMerit Medical Systems Inc. | 84.17 | -1.08% | $5.03B | vs HAE |
| HTFLHeartflow Inc. | 48.15 | -2.45% | $4.19B | vs HAE |
| TFXTeleflex Incorporated | 123.60 | -0.71% | $5.24B | vs HAE |
| STVNStevanato Group S.p.A. | 19.22 | -1.13% | $5.25B | vs HAE |
| MMEDMiniMed Group Inc. | 19.49 | +1.99% | $5.48B | vs HAE |
| ICUIICU Medical Inc. | 154.85 | -0.76% | $3.87B | vs HAE |
| NVSTEnvista Holdings Corporation | 22.65 | -1.69% | $3.64B | vs HAE |
| PLSEPulse Biosciences Inc | 47.97 | -2.28% | $3.42B | vs HAE |
Indexes, lists and sector
Haemonetics stock FAQ
What is Haemonetics's stock price today?
HAE last traded at $115.80 as of Oct 8, 10:03 AM EDT, up 13.85% on the day. Prices are delayed at least 15 minutes.
Does Haemonetics pay a dividend?
No. Haemonetics does not currently pay a regular cash dividend.
When is Haemonetics's next earnings date?
Haemonetics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $1.30.
What is HAE's P/E ratio?
HAE trades at a trailing P/E ratio of 55.94 and a forward P/E of 20.04, compared with a median of 36.8 for its closest peers.
Who is Haemonetics's CEO?
Mr. Christopher A. Simon is the chief executive officer of Haemonetics Corporation, which has about 3,009 employees.
Has HAE ever split its stock?
Yes. The most recent HAE stock split was a 2-for-1 split on Dec 3, 2012, one of 2 splits on record.
What is the HAE 52-week high?
The 52-week high for HAE is $120.72 and the 52-week low is $48.17. The stock is currently 4.1% below its high.